Emulate to collaborate with Seres Therapeutics to support the development of novel microbiome therapeutics
Seres to use Emulate's Intestine-Chip technology to identify promising new microbiome therapeutic candidates for inflammatory bowel disease.
Seres Therapeutics has announced a new collaboration. Under the terms of the agreement, Seres and Emulate will work to further advance Emulate’s Intestine-Chip platform, a micro-engineered, living-tissue-based system that models the human intestine. Seres intends to use the technology to identify novel bacteria compositions with therapeutic potential.
“Emulate has developed a highly innovative technology platform consisting of multiple human cell types that may be far more accurate in recreating human gastrointestinal tissue and its interaction with the microbiome than conventional cell culture approaches,” said David Cook, Executive Vice President of R&D and Chief Scientific Officer of Seres. “We expect Emulate’s technology platform will enhance our approach for drug discovery and accelerate our efforts to identify promising new microbiome therapeutic candidates for inflammatory bowel disease, other autoimmune or immunological conditions, infectious diseases, and other serious disease states, which may have a microbiome therapeutic based solution.”
“We are extremely pleased to work with Seres, a leader in the development of microbiome therapeutics, and apply our Organs-on-Chips technology to enhance drug discovery in an emerging field, such as the microbiome,” said James Coon, CEO of Emulate. “The microbiome represents a critically important new area of medicine, and our ‘Intestine-Chip’ is remarkably well suited to evaluate complex biological mechanisms, such as the impact of bacterial compositions on the integrity of the gut barrier and mechanisms of healing in response to inflammation. By combining Emulate’s human-relevant Organs-on-Chips technology with the therapeutic expertise from biopharmaceutical leaders such as Seres, Emulate aims to meaningfully contribute to improving human health.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance